{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:36:10Z","timestamp":1788554170794,"version":"build-2803163510"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Finnish Cancer Registry","award":["H3710"],"award-info":[{"award-number":["H3710"]}]},{"name":"State funding for university level health research","award":["TYH 2019206"],"award-info":[{"award-number":["TYH 2019206"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by biliary strictures, cholestasis, and a markedly increased risk of cholangiocarcinoma. New markers for the screening and differential diagnosis of PSC are needed. In this pilot study, we have analyzed both the bile and serum proteomic profiles of 80 PSC patients and non-PSC controls (n = 6 for bile and n = 18 for serum).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Aim<\/jats:title>\n<jats:p>The aim of this study was to discover candidates for new biomarkers for the differential diagnosis of PSC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Bile and serum samples were processed and subsequently analyzed using ultra performance liquid chromatography-ultra definition mass spectrometry (UPLC-UDMS<jats:sup>E<\/jats:sup>). Further analysis included statistical analyses such as receiver operating characteristic curve analysis as well as pathway analysis using Ingenuity Pathway Analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results and conclusions<\/jats:title>\n<jats:p>In bile, we discovered 64 proteins with significantly different levels between the groups, with fold changes of up to 129. In serum, we discovered 112 proteins with significantly different levels. Receiver operating characteristic curve analysis found multiple proteins with high area under the curve values, up to 0.942, indicating that these serum proteins are of value as new non-invasive classifiers of PSC. Pathway analysis revealed multiple canonical pathways that were enriched in the dataset, which have roles in bile homeostasis and metabolism. We present several serum proteins that could serve as new blood-based markers for the diagnosis of PSC after further validation. The measurement of serum levels of these proteins could be of use in the screening of patients with suspected PSC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0272810","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T17:45:13Z","timestamp":1661449513000},"page":"e0272810","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quantitative bile and serum proteomics for the screening and differential diagnosis of primary sclerosing cholangitis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8453-3936","authenticated-orcid":true,"given":"Matilda","family":"Holm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakari","family":"Joenv\u00e4\u00e4r\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiialotta","family":"Tohmola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Arola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto","family":"Renkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martti","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"6","key":"pone.0272810.ref001","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014a comprehensive review","volume":"67","author":"TH Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0272810.ref002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"A Bergquist","year":"2002","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0272810.ref003","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/00365521.2014.946085","article-title":"Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"50","author":"P Manninen","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"pone.0272810.ref004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland","volume":"55","author":"N Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"10139","key":"pone.0272810.ref005","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"JK Dyson","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"pone.0272810.ref006","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis","volume":"152","author":"TJ Weismuller","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0272810.ref007","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"K Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"pone.0272810.ref008","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG Clinical Guideline: Primary Sclerosing Cholangitis","volume":"110","author":"KD Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"pone.0272810.ref009","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"R Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"pone.0272810.ref010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.21405","article-title":"Sclerosing cholangitis: a focus on secondary causes","volume":"44","author":"R Abdalian","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"pone.0272810.ref011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.24103","article-title":"Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis","volume":"53","author":"TO Lankisch","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"pone.0272810.ref012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/gastro\/gou066","article-title":"Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study","volume":"3","author":"U Navaneethan","year":"2015","journal-title":"Gastroenterol Rep (Oxf)."},{"issue":"1","key":"pone.0272810.ref013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/gutjnl-2012-302047","article-title":"Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders","volume":"62","author":"J Metzger","year":"2013","journal-title":"Gut"},{"issue":"6","key":"pone.0272810.ref014","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","author":"M Vesterhus","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0272810.ref015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0041-110792","article-title":"Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia","volume":"48","author":"S Boyd","year":"2016","journal-title":"Endoscopy"},{"issue":"7","key":"pone.0272810.ref016","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cam4.1107","article-title":"Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis","volume":"6","author":"M Saraswat","year":"2017","journal-title":"Cancer Med"},{"key":"pone.0272810.ref017","article-title":"Plasma protein expression differs between colorectal cancer patients depending on primary tumor location","author":"M Holm","year":"2020","journal-title":"Cancer Medicine"},{"issue":"1","key":"pone.0272810.ref018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1074\/mcp.M500230-MCP200","article-title":"Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition","volume":"5","author":"JC Silva","year":"2006","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"pone.0272810.ref019","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1021\/pr300426s","article-title":"Recognizing uncertainty increases robustness and reproducibility of mass spectrometry-based protein inferences","volume":"11","author":"O Serang","year":"2012","journal-title":"J Proteome Res"},{"issue":"D1","key":"pone.0272810.ref020","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","article-title":"2016 update of the PRIDE database and its related tools","volume":"44","author":"JA Vizcaino","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"pone.0272810.ref021","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkw936","article-title":"The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition","volume":"45","author":"EW Deutsch","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"pone.0272810.ref022","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"T Claudel","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"pone.0272810.ref023","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"JR Schultz","year":"2000","journal-title":"Genes Dev"},{"issue":"4","key":"pone.0272810.ref024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"AC Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"pone.0272810.ref025","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.","volume":"70","author":"M Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"pone.0272810.ref026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2559.2009.03258.x","article-title":"Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis","volume":"54","author":"A Aigelsreiter","year":"2009","journal-title":"Histopathology"},{"issue":"4 Pt B","key":"pone.0272810.ref027","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbadis.2017.09.012","article-title":"Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis","volume":"1864","author":"C Rupp","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T17:45:46Z","timestamp":1661449546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272810"}},"subtitle":[],"editor":[{"given":"Aleksandra","family":"Nita-Lazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0272810","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}